Dipyridamole Tablets are indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement.
Arthur Bedrosian, president and CEO of Lannett, said: “As we enter our 66th year of providing low cost alternative generic drugs, we welcome this new addition to our line. We expect to commence marketing all three dosages of our dipyridamole product in this quarter.”